» Articles » PMID: 9095468

Fructose 2,6-bisphosphate Metabolism During Megakaryocytic Differentiation of K562 and MEG-01 Cells

Overview
Publisher Springer
Specialty Biochemistry
Date 1996 Mar 23
PMID 9095468
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Fructose 2,6-bisphosphate (Fru-2, 6-P2) represents the most powerful activator of 6-phosphofructo-1-kinase, rate-limiting enzyme of glycolysis. Fru-2,6-P2 content is tightly regulated and appears to be under the control of different hormones and growth factors, acting either through covalent modification of isoenzymatic forms of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase (PFK-2/FBPase-2), the bifunctional enzyme responsible for the synthesis and the degradation of the compound, or through changes in transcription rate and/or in the expression of different isoforms of the enzyme. In the present study the metabolism of Fru-2,6-P2 was investigated during the differentiation toward megakaryocytes induced by phorbol 12-myristate 13-acetate (PMA) treatment of human leukemia K562 and MEG-01 cell lines. Fru-2,6-P2 content as well as PFK-2 activity were increased in a dose-dependent manner after 4 days of incubation with PMA. MEG-01 cells resulted more sensitive to the effect of the inducer, anyway in both cell types cytostatic concentrations of the phorbol ester were able to affect Fru-2,6-P2 metabolism. The effect of PMA was maximal at 4 days of incubation in both examined cell lines. Interestingly, the effect induced by the phorbol ester at 4 days was still appreciable subculturing K562 and MEG-01 cells for 3 days in the absence of the inducer and was associated with relevant changes in the molecular properties of PFK-2: namely increased Vmax and K(m). This latter finding suggests that the rise in Fru-2,6-P2 content during the differentiation process toward megakaryocytes might result from the expression of a novel PFK-2 isoform.

Citing Articles

Human serotonin transporter expression during megakaryocytic differentiation of MEG-01 cells.

Giannaccini G, Betti L, Palego L, Schmid L, Fabbrini L, Pelosini C Neurochem Res. 2009; 35(4):628-35.

PMID: 20041293 DOI: 10.1007/s11064-009-0112-8.


6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis.

Rider M, Bertrand L, Vertommen D, Michels P, Rousseau G, Hue L Biochem J. 2004; 381(Pt 3):561-79.

PMID: 15170386 PMC: 1133864. DOI: 10.1042/BJ20040752.

References
1.
Bruni P, Vasta V, Farnararo M . Adenylate cyclase stimulating agents and mitogens raise fructose 2,6-bisphosphate levels in human fibroblasts. Evidence for a dual control of the metabolite. FEBS Lett. 1987; 222(1):27-31. DOI: 10.1016/0014-5793(87)80185-0. View

2.
Colomer D, Corrons J, Bartrons R . Effect of TPA on fructose 2,6-bisphosphate levels and protein kinase C activity in B-chronic lymphocytic leukemia (B-CLL). Biochim Biophys Acta. 1991; 1097(4):270-4. DOI: 10.1016/0925-4439(91)90080-s. View

3.
Hoffman R . Regulation of megakaryocytopoiesis. Blood. 1989; 74(4):1196-212. View

4.
Hue L, Rider M . Role of fructose 2,6-bisphosphate in the control of glycolysis in mammalian tissues. Biochem J. 1987; 245(2):313-24. PMC: 1148124. DOI: 10.1042/bj2450313. View

5.
Baulida J, Onetti R, Bassols A . Effects of epidermal growth factor on glycolysis in A431 cells. Biochem Biophys Res Commun. 1992; 183(3):1216-23. DOI: 10.1016/s0006-291x(05)80320-1. View